Lung Cancer Treatment
NSCLC and Personalized Therapy

Non-small cell lung cancer (NSCLC) treatment is increasingly personalized. Instead of choosing treatment only by cancer stage, oncologists now review pathology, imaging, molecular markers, PD-L1 status, previous treatment and overall fitness before recommending surgery, radiation, chemotherapy, targeted therapy, immunotherapy or clinical trials. This page helps patients and families understand how NSCLC treatment decisions are made and how CancerFax supports report review, second opinions and advanced treatment access. Primary CTA: Share Your Reports. Secondary CTA: Request Treatment Guidance.

Personalized therapy becomes important as soon as NSCLC is diagnosed, especially if the disease is advanced, recurrent or metastatic. The National Cancer Institute notes that NSCLC treatment options are determined by histology, stage, general health and comorbidities, and may include surgery, radiation therapy, chemotherapy, targeted agents, immunotherapy and supportive measures. For many patients, starting treatment before complete pathology and biomarker review can lead to missed opportunities or sequencing problems.

Families often begin searching because they have heard about targeted therapy or immunotherapy but do not know whether it applies to their case. Some patients are told they have adenocarcinoma, squamous NSCLC or stage 4 lung cancer without receiving a clear explanation of molecular testing. Others progress after first-line treatment and need to know whether another drug, a clinical trial or treatment abroad should be considered. CancerFax helps bring structure to these decisions.

NSCLC includes lung cancers other than small cell lung cancer. Common subtypes include adenocarcinoma, squamous cell carcinoma and large cell carcinoma. Personalized therapy means the treatment plan is based on the biology of the tumor and the patient’s condition, not only on the diagnosis name. In practice, this may involve confirming pathology, staging the disease with CT, PET-CT or brain MRI, checking biomarker results, reviewing previous treatment response and deciding whether local treatment, systemic therapy or a trial is appropriate.

Treatment may include surgery for selected early-stage tumors, stereotactic or conventional radiation when surgery is not suitable, chemotherapy, immunotherapy, targeted therapy, anti-angiogenic therapy, combinations and palliative care for symptom control. The American Cancer Society explains that targeted drugs are developed to specifically target changes in NSCLC cells that help them grow. Examples include drugs directed at EGFR mutations, ALK or ROS1 rearrangements, KRAS G12C, BRAF, MET, RET and NTRK alterations, depending on the patient’s test results and regulatory availability.

Suitability depends on NSCLC subtype, TNM stage, tumor location, spread to lymph nodes or distant organs, performance status, lung function, cardiac fitness, organ function, autoimmune history, biomarker findings and prior treatment. A patient with an actionable mutation may be considered for targeted therapy, while a patient without a driver mutation may be reviewed for immunotherapy, chemotherapy or combinations based on PD-L1 and clinical factors. No patient should be assumed eligible without oncologist review.

A complete review usually needs the biopsy or surgery pathology report, IHC report, staging scans, PET-CT if performed, brain MRI where relevant, NGS or molecular testing report, PD-L1 report, blood tests, lung function results if surgery or radiation is being considered, treatment history, discharge summaries, current medicines and the treating doctor’s latest opinion. If tissue is limited, specialists may consider whether repeat biopsy or liquid biopsy is appropriate.

CancerFax helps patients collect and organize records, understand the current stage and treatment problem, identify missing tests, coordinate second opinions, support biomarker-based treatment review, and connect eligible patients with hospitals or specialists. For international care, CancerFax can assist with cost clarity, admission coordination, interpreter support, travel planning and post-treatment communication. The goal is not to push one therapy, but to help families understand realistic, case-specific options.

Costs vary widely depending on country, hospital type, diagnostic testing, surgery or radiation needs, targeted drug choice, immunotherapy schedule, number of cycles, management of complications, trial availability and follow-up. Early-stage treatment may require surgery and a shorter admission, while metastatic NSCLC may involve long-term outpatient treatment. International patients should plan for accommodation, caregiver stay, translation, repeat scans and ongoing communication with the treating team.

Personalized therapy does not guarantee response. Targeted drugs can stop working because resistance develops. Immunotherapy may cause immune-related side effects affecting the lungs, bowel, liver, endocrine glands, kidneys or skin. Chemotherapy and radiation can also cause important toxicities. Some patients are too unstable to travel or need urgent local care. Final decisions must be made by qualified oncologists after reviewing all clinical details.

NSCLC personalized therapy may be available in government cancer centres, university hospitals, private oncology hospitals and clinical trial units. Access differs by country and centre, especially for broad NGS testing, newer targeted drugs, immunotherapy combinations and trial-based treatments. Patients considering treatment abroad should confirm diagnosis, biomarker profile, treatment intent, expected timeline and follow-up arrangements before travel.

Frequently Asked Questions

Answers to common questions from patients and families.

If you or a family member has NSCLC, share the pathology, imaging and biomarker reports with CancerFax. A structured review can help clarify whether surgery, radiation, targeted therapy, immunotherapy, chemotherapy, a clinical trial or an international treatment pathway should be discussed with specialists.

[1] National Cancer Institute. Non-Small Cell Lung Cancer Treatment (PDQ®). https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq [2] American Cancer Society. Targeted Drug Therapy for Non-small Cell Lung Cancer. https://www.cancer.org/cancer/types/lung-cancer/treating-non-small-cell/targeted-therapies.html

Structured reference data summarizing key information for this topic.

Structured reference data summarizing key information for this topic.